Navigation Links
Imagenetix, Inc. Reports Third Quarter 2011 Results
Date:2/25/2011

SAN DIEGO, Feb. 25, 2011 /PRNewswire/ -- Imagenetix, Inc. (OTC Bulletin Board: IAGX) announced today results for the three and nine months ended December 31, 2010. Net sales decreased 4% for the third quarter of fiscal year 2011 to $1,696,000 from $1,765,000 for the same period of last year. A loss of $1,202,000, $0.10 per share, was reported for the third quarter of fiscal year 2011, compared to a net loss of $294,000, $.03 per share, for the same period of the prior fiscal year.  

For the nine months ended December 31, 2010, net sales increased 11% to $6,001,000 from $5,368,000 for the same period the previous fiscal year.  The company reported a net loss of $1,736,000, $0.15 per share, compared to a net loss of $156,000, $0.01 per share, for the previous fiscal year.  The previous fiscal year included one-time before tax settlement income of $1,250,000.

Commenting on the results of the third quarter, Mr. William Spencer, Imagenetix Chief Executive Officer said: "The loss during the quarter was driven by our advertising and promotional campaigns.  Although quarterly sales to the mass market segment increased by 66% for the quarter, it was not enough to offset reductions in the wholesale and distribution segment sales.  This was coupled with a significant increase in advertising and sales promotions to introduce consumers to our product line that now reaches nation-wide for Celadrin softgels and BioGuard, and throughout the west for Celadrin cream.  We held many product demonstrations, offered manufacturers rebates and advertised in both print and national television media.  We recognize this to be the most effective way to increase product exposure and impact sales and product recognition over the long term. In addition, we continue to analyze strategic alliances for our array of intellectual properties as well as exploring sale of non-strategic assets."

About Imagenetix

Imagenetix, based in San Diego, California, is an innovator of scientifically tested, natural-based, proprietary, bioceutical products developed to enhance human health on a global basis.  Imagenetix develops and formulates propriety over-the-counter topical creams, skincare products and nutritional supplements to be marketed globally through multiple channels of distribution.  In addition, the company develops patentable compounds for entering into licensing agreements with pharmaceutical partners.  Imagenetix is the creator of Celadrin®.  Please visit, www.celadrin.com, www.bioguardhealth.com or www.imagenetix.net.

Certain matters in this news release are forward-looking statements which are subject to risks and uncertainties that could cause actual results to vary materially from those projected.  Such risks and uncertainties include, but are not limited to, adverse fluctuations in future operating results due to a number of economic, competitive, and other factors, including, among other things, the size and timing of customer contracts, new or increased competition, changes in market demand, and seasonality of purchases of the company's products and services.  Additional information with respect to these and other factors, which could materially affect the company and its operations, are included in the company's SEC filings, including its Form 10-K for the year ended March 31, 2010.Imagenetix, Inc. Condensed Consolidated Statements of Operations(Unaudited)(In thousands, except per share data)Three Months EndedNine Months EndedDecember 31,December 31,2010200920102009Net sales$

1,696$

1,765$

6,001$

5,368   Cost of sales1,2798783,4602,973Gross profit4178872,5412,395Gross profit percent24.6%50.3%42.3%44.6%Operating expenses:Selling, general and administrative1,8165733,2881,956Payroll expense272325834849Consulting expense3534341,1061,009Operating expenses 2,4411,3325,2283,814Operating loss(2,024)(445)(2,687)(1,419)Other income-316Settlement income---1,250Interest expense (44)-(158)(2)Loss before income taxes(2,068)(442)(2,844)(165)Income tax benefit(866)(148)(1,108)(9)Net loss$

(1,202)$

(294)$

(1,736)$

(156)Loss per share:Basic and diluted$

(0.10)$

(0.03)$

(0.15)$

(0.01)Weighted average common shares outstanding:Basic and diluted11,81111,01111,64511,011Imagenetix, Inc. Condensed Consolidated Balance Sheets(Unaudited)(In thousands) December 31,

March 31, 2010 2010 Assets:Current assets:Cash and cash equivalents

$

171$

981Accounts receivable, net9591,049Inventories, net9881,350Prepaid expenses and other current assets282151Deferred tax asset2,034933   Total current assets4,4344,464Property and equipment, net 6789Long-term prepaid expenses918Other assets 117125   Total assets

$

4,627$

4,696Liabilities and stockholders' equity:Current liabilities:Secured note payable to bank

$

1,025$

-Convertible notes294-Accounts payable710997Accrued liabilities6783Customer deposits2225Contract payable7586   Total current liabilities2,1931,191Stockholders' equity 2,4343,505   Total liabilities and stockholders' equity

$

4,627$

4,696ContactImagenetix Investor Relations

William P. Spencer(858)385-2797

Chief Executive OfficerImagenetix, Inc.Tel: (858) 674-8455
'/>"/>

SOURCE Imagenetix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Letter to Shareholders From Imagenetix, Inc. President/CEO William Spencer
2. Imagenetix, Inc. Provides Net Sales Guidance for the Second Quarter Fiscal 2011
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Spherix Reports Second Quarter Earnings
5. Tapestry Reports Second Quarter 2007 Results
6. Callisto Reports on Second-Quarter 2007 Milestones
7. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
8. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
11. Biopure Reports on Meeting with the FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... the Dow Jones Industrial Average edged 0.36% higher, to finish ... 0.35%. Losses were broad based as six out of nine ... research reports on the following Services equities: Myriad Genetics Inc. ... QGEN ), INC Research Holdings Inc. (NASDAQ: INCR ...
(Date:12/2/2016)... 2016 The concept of rare diseases and the ... this sector has been taking shape in Europe ... aspects and initiatives related to orphan medicinal products have been ... of member states individually. Many member states in the EU ... of orphan medicinal products, the result of which took the ...
(Date:12/2/2016)... 1, 2016 Around the corners of world, ... each habitable land present over earth. Cancer has become ... in a life time this is because of the ... now. Given the steady increase in global cancer incidence ... spiraling healthcare costs of treatment, there is increasing interest ...
Breaking Medicine Technology:
(Date:12/4/2016)... ... December 03, 2016 , ... While James Earl Jones is known for myriad ... a show called "Front Page". One of the forthcoming episodes examines mammogram techniques; a ... plummeted in large part due to early detection. Like any other disease, treatments have ...
(Date:12/4/2016)... ... December 04, 2016 , ... Patients ... can now take advantage of a cosmetic procedure known as Carbon Dioxide ... reduces the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, ...
(Date:12/2/2016)... ... , ... Lori G. Cohen and Sara K. Thompson , ... American Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place ... conference. , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation ...
(Date:12/2/2016)... AL (PRWEB) , ... December 02, 2016 , ... ... from across the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF ... Schmitz, will help provide scholarship funds for area students and operating support to ...
(Date:12/2/2016)... ... ... The annual time frame to change Medicare health and prescription drug coverage, known ... Medicare beneficiaries who are looking to switch from their current plan to a Medicare ... during this period order for their new policy to go into effect in 2017. ...
Breaking Medicine News(10 mins):